KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Novavax (NVAX) Leases (2019 - 2025)

Novavax (NVAX) has 7 years of Leases data on record, last reported at $20.3 million in Q4 2025.

  • For Q4 2025, Leases fell 85.45% year-over-year to $20.3 million; the TTM value through Dec 2025 reached $20.3 million, down 85.45%, while the annual FY2025 figure was $20.3 million, 85.45% down from the prior year.
  • Leases reached $20.3 million in Q4 2025 per NVAX's latest filing, down from $139.7 million in the prior quarter.
  • Across five years, Leases topped out at $160.2 million in Q4 2023 and bottomed at $20.3 million in Q4 2025.
  • Average Leases over 5 years is $84.7 million, with a median of $86.1 million recorded in 2022.
  • Peak YoY movement for Leases: soared 414.79% in 2021, then plummeted 85.45% in 2025.
  • A 5-year view of Leases shows it stood at $40.1 million in 2021, then fell by 9.32% to $36.4 million in 2022, then soared by 340.39% to $160.2 million in 2023, then dropped by 12.79% to $139.7 million in 2024, then tumbled by 85.45% to $20.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $20.3 million in Q4 2025, $139.7 million in Q4 2024, and $160.2 million in Q4 2023.